Clover Health Investments vs Guardant Health: why the prices moved differently

Weekly · monthly · quarterly news summaries, side by side in time

Clover Health Investments Corp (CLOV)

Q3 202618 Jun – 14 Aug 2026

▲3

Clover wins star-rating lawsuit, posts profit, raises guidance

Star-rating lawsuit win could restore $120M in bonuses Clover won a lawsuit forcing Medicare to recalculate its star ratings, potentially restoring about $120 million in bonus payments. Higher stars mean more government money and cheaper marketing, directly boosting profit. Rival Elevance is suing over the same decision, so the benefit could shrink or face delays.
This regulatory win is a major new force behind CLOV's outlook and price.
Q2 profit and raised 2026 guidance Clover reported Q2 revenue of $743 million, up from $478 million, and swung to a $28 million profit from a loss. It raised full-year guidance to as much as $3 billion revenue and $35 million net income. Turning profitable is a big deal for a company investors once doubted.
The profit swing and guidance raise are the clearest new evidence of improving finances.
Fast membership growth and lower medical costs Clover's Medicare Advantage membership grew strongly while its medical cost ratio fell, meaning it kept more of each premium dollar. Its AI tool, Clover Assistant, is helping control costs. This combination of growth and better underwriting supports the stock because it shows the business can scale profitably.
These operating drivers explain why results beat expectations and support the stock.

July 202618 Jun – 14 Aug 2026

▲3

Clover wins star-rating lawsuit, posts profit, raises guidance

Star-rating lawsuit win could restore $120M in bonuses Clover won a lawsuit forcing Medicare to recalculate its star ratings, potentially restoring about $120 million in bonus payments. Higher stars mean more government money and cheaper marketing, directly boosting profit. Rival Elevance is suing over the same decision, so the benefit could shrink or face delays.
This regulatory win is a major new force behind CLOV's outlook and price.
Q2 profit and raised 2026 guidance Clover reported Q2 revenue of $743 million, up from $478 million, and swung to a $28 million profit from a loss. It raised full-year guidance to as much as $3 billion revenue and $35 million net income. Turning profitable is a big deal for a company investors once doubted.
The profit swing and guidance raise are the clearest new evidence of improving finances.
Fast membership growth and lower medical costs Clover's Medicare Advantage membership grew strongly while its medical cost ratio fell, meaning it kept more of each premium dollar. Its AI tool, Clover Assistant, is helping control costs. This combination of growth and better underwriting supports the stock because it shows the business can scale profitably.
These operating drivers explain why results beat expectations and support the stock.

Latest18 Jun – 14 Aug 2026

▲3

Clover wins star-rating lawsuit, posts profit, raises guidance

Star-rating lawsuit win could restore $120M in bonuses Clover won a lawsuit forcing Medicare to recalculate its star ratings, potentially restoring about $120 million in bonus payments. Higher stars mean more government money and cheaper marketing, directly boosting profit. Rival Elevance is suing over the same decision, so the benefit could shrink or face delays.
This regulatory win is a major new force behind CLOV's outlook and price.
Q2 profit and raised 2026 guidance Clover reported Q2 revenue of $743 million, up from $478 million, and swung to a $28 million profit from a loss. It raised full-year guidance to as much as $3 billion revenue and $35 million net income. Turning profitable is a big deal for a company investors once doubted.
The profit swing and guidance raise are the clearest new evidence of improving finances.
Fast membership growth and lower medical costs Clover's Medicare Advantage membership grew strongly while its medical cost ratio fell, meaning it kept more of each premium dollar. Its AI tool, Clover Assistant, is helping control costs. This combination of growth and better underwriting supports the stock because it shows the business can scale profitably.
These operating drivers explain why results beat expectations and support the stock.

Guardant Health Inc (GH)

Q3 202624 Jun – 30 Jul 2026

▲2▼1

Guardant's Shield Wins Insurance Coverage and Sales Surge, Lifting Guidance

UnitedHealth covers Shield blood test UnitedHealth, America's largest commercial insurer, became the first big insurer to cover Guardant's Shield blood test for colorectal cancer screening. Over 100 million people can now get it. More covered patients means more test sales, pushing revenue and the stock up.
This is a major new demand catalyst that directly expands the market for Guardant's key screening product.
Q2 revenue jumps 44%, guidance raised Guardant reported second-quarter revenue of $335 million, up 44% from a year ago, and raised its full-year 2026 revenue outlook to $1.34–$1.36 billion. Oncology test volume grew 63% and Shield screening revenue more than tripled. Strong growth signals the business is scaling, which supports a higher stock price.
This is the latest hard financial evidence of accelerating demand and management confidence, a core driver of the stock.
Quest's Haystack MRD test goes nationwide Quest Diagnostics won New York approval for its Haystack MRD liquid biopsy test, clearing it for use in all 50 states. This puts a large, well-funded competitor directly into cancer monitoring, where Guardant also plays. More competition could pressure Guardant's pricing and market share, a real counterweight.
It is a new competitive threat that could limit Guardant's growth in the cancer-monitoring market.

July 202624 Jun – 30 Jul 2026

▲2▼1

Guardant's Shield Wins Insurance Coverage and Sales Surge, Lifting Guidance

UnitedHealth covers Shield blood test UnitedHealth, America's largest commercial insurer, became the first big insurer to cover Guardant's Shield blood test for colorectal cancer screening. Over 100 million people can now get it. More covered patients means more test sales, pushing revenue and the stock up.
This is a major new demand catalyst that directly expands the market for Guardant's key screening product.
Q2 revenue jumps 44%, guidance raised Guardant reported second-quarter revenue of $335 million, up 44% from a year ago, and raised its full-year 2026 revenue outlook to $1.34–$1.36 billion. Oncology test volume grew 63% and Shield screening revenue more than tripled. Strong growth signals the business is scaling, which supports a higher stock price.
This is the latest hard financial evidence of accelerating demand and management confidence, a core driver of the stock.
Quest's Haystack MRD test goes nationwide Quest Diagnostics won New York approval for its Haystack MRD liquid biopsy test, clearing it for use in all 50 states. This puts a large, well-funded competitor directly into cancer monitoring, where Guardant also plays. More competition could pressure Guardant's pricing and market share, a real counterweight.
It is a new competitive threat that could limit Guardant's growth in the cancer-monitoring market.

Latest24 Jun – 30 Jul 2026

▲2▼1

Guardant's Shield Wins Insurance Coverage and Sales Surge, Lifting Guidance

UnitedHealth covers Shield blood test UnitedHealth, America's largest commercial insurer, became the first big insurer to cover Guardant's Shield blood test for colorectal cancer screening. Over 100 million people can now get it. More covered patients means more test sales, pushing revenue and the stock up.
This is a major new demand catalyst that directly expands the market for Guardant's key screening product.
Q2 revenue jumps 44%, guidance raised Guardant reported second-quarter revenue of $335 million, up 44% from a year ago, and raised its full-year 2026 revenue outlook to $1.34–$1.36 billion. Oncology test volume grew 63% and Shield screening revenue more than tripled. Strong growth signals the business is scaling, which supports a higher stock price.
This is the latest hard financial evidence of accelerating demand and management confidence, a core driver of the stock.
Quest's Haystack MRD test goes nationwide Quest Diagnostics won New York approval for its Haystack MRD liquid biopsy test, clearing it for use in all 50 states. This puts a large, well-funded competitor directly into cancer monitoring, where Guardant also plays. More competition could pressure Guardant's pricing and market share, a real counterweight.
It is a new competitive threat that could limit Guardant's growth in the cancer-monitoring market.